Bank of New York Mellon Corp - CORBUS PHARMACEUTICALS HLDGS ownership

CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 64 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q4 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.

Quarter-by-quarter ownership
Bank of New York Mellon Corp ownership history of CORBUS PHARMACEUTICALS HLDGS
ValueSharesWeighting
Q4 2022$3,543
-29.1%
32,061
-6.5%
0.00%
Q3 2022$5,000
-44.4%
34,3010.0%0.00%
Q2 2022$9,000
-50.0%
34,3010.0%0.00%
Q1 2022$18,000
-14.3%
34,3010.0%0.00%
Q4 2021$21,000
-40.0%
34,3010.0%0.00%
Q3 2021$35,000
-90.3%
34,301
-82.6%
0.00%
Q2 2021$361,000
-31.5%
197,232
-26.2%
0.00%
Q1 2021$527,000
+86.9%
267,113
+18.0%
0.00%
Q4 2020$282,000
-42.7%
226,423
-17.0%
0.00%
Q3 2020$492,000
-78.3%
272,780
+0.8%
0.00%
-100.0%
Q2 2020$2,270,000
+98.6%
270,618
+24.2%
0.00%
Q1 2020$1,143,000
+5.1%
217,916
+9.4%
0.00%
Q4 2019$1,088,000
+14.4%
199,193
+2.1%
0.00%
Q3 2019$951,000
-34.7%
195,168
-7.1%
0.00%
Q2 2019$1,456,000
+1.7%
210,134
+2.0%
0.00%
Q1 2019$1,432,000
+26.2%
206,019
+6.0%
0.00%
Q4 2018$1,135,000
-15.6%
194,374
+9.2%
0.00%
Q3 2018$1,344,000
+41.8%
178,069
-5.1%
0.00%
Q2 2018$948,000
-18.1%
187,695
-1.1%
0.00%
Q1 2018$1,157,000
-14.0%
189,756
+0.1%
0.00%
Q4 2017$1,346,000
+25.4%
189,578
+26.3%
0.00%
Q3 2017$1,073,000
+24.5%
150,135
+9.7%
0.00%
Q2 2017$862,000
+395.4%
136,812
+548.3%
0.00%
Q1 2017$174,000
+4.8%
21,102
+7.7%
0.00%
Q4 2016$166,000
+7.1%
19,591
-14.4%
0.00%
Q3 2016$155,00022,8820.00%
Other shareholders
CORBUS PHARMACEUTICALS HLDGS shareholders Q4 2022
NameSharesValueWeighting ↓
Ikarian Capital, LLC 397,168$43,8880.01%
CJM Wealth Advisers, Ltd. 30,465$3,3660.00%
Tekla Capital Management LLC 154,310$17,0510.00%
McAdam, LLC 10,006$60.00%
Aries Wealth Management 15,400$1,7020.00%
WELLS FARGO & COMPANY/MN 342,084$37,8000.00%
JPMORGAN CHASE & CO 43,415$50.00%
NORTHERN TRUST CORP 207,329$22,9100.00%
PINNACLE ASSOCIATES LTD 18,580$2,0530.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
View complete list of CORBUS PHARMACEUTICALS HLDGS shareholders